Compass Pathways (NASDAQ:CMPS) Rating Lowered to Strong Sell at Wall Street Zen

Compass Pathways (NASDAQ:CMPS) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Monday.

Other research analysts have also recently issued research reports about the company. Oppenheimer reiterated an “outperform” rating on shares of Compass Pathways in a research note on Wednesday, August 5th. Royal Bank Of Canada reduced their price target on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Raymond James Financial reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. HC Wainwright cut their price objective on shares of Compass Pathways from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Maxim Group raised their price objective on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Compass Pathways presently has an average rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Trading Up 4.8%

CMPS opened at $14.88 on Monday. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. Compass Pathways has a 52 week low of $4.40 and a 52 week high of $15.40. The stock has a market cap of $2.06 billion, a PE ratio of -3.22 and a beta of 2.50. The business has a 50 day moving average of $12.97 and a 200-day moving average of $9.94.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). Equities research analysts predict that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Corient Private Wealth LLC increased its position in Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after acquiring an additional 1,200 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares during the period. Ancora Advisors LLC purchased a new stake in shares of Compass Pathways during the 2nd quarter valued at about $43,000. Conservest Capital Advisors Inc. increased its position in shares of Compass Pathways by 24.6% during the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Compass Pathways during the 4th quarter valued at about $38,000. 46.19% of the stock is owned by institutional investors.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.